LXRX

1.46

1.39% 0.02

Vorhandelsmarkt: 1.46

Lexicon Pharmaceuticals Inc (LXRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt LXRX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.44

Offen:

$1.44

24-Stunden-Volumen:

1.83M

Relative Volume:

0.70

Marktkapitalisierung:

$530.56M

Einnahmen:

$1.21M

Nettoeinkommen (Verlust:

$-177.12M

KGV:

-1.825

EPS:

-0.8

Netto-Cashflow:

$-162.37M

1W Leistung:

-3.95%

1M Leistung:

+26.96%

6M Leistung:

+175.47%

1J Leistung:

-18.44%

1-Tages-Spanne:

$1.4215

$1.485

1-Wochen-Bereich:

$1.40

$1.66

52-Wochen-Spanne:

$0.2836

$2.175

Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile

Firmenname

Lexicon Pharmaceuticals Inc

Sektor

Healthcare (1140)

Branche

Biotechnology (636)

Telefon

(281) 863-3000

Adresse

2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS

Mitarbeiter

103

Twitter

@LexPharma

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

LXRX's Discussions on Twitter

Vergleichen Sie LXRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LXRX Lexicon Pharmaceuticals Inc	1.46	541.46M	1.21M	-177.12M	-162.37M	-0.80
VRTX Vertex Pharmaceuticals Inc	412.22	104.45B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	469.36	60.95B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	572.60	59.11B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	812.95	49.23B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.94	35.92B	4.56B	-176.77M	225.30M	-1.7177

Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-05	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-06-17	Eingeleitet	H.C. Wainwright	Buy
2024-04-30	Eingeleitet	Leerink Partners	Outperform
2023-03-07	Eingeleitet	Jefferies	Hold
2022-08-12	Eingeleitet	Piper Sandler	Overweight
2021-01-29	Hochstufung	JP Morgan	Underweight → Neutral
2021-01-29	Herabstufung	Wedbush	Outperform → Neutral
2020-12-08	Hochstufung	Citigroup	Neutral → Buy
2020-11-18	Hochstufung	Gabelli & Co	Hold → Buy
2019-12-11	Herabstufung	Gabelli & Co	Buy → Hold
2019-11-08	Herabstufung	Citigroup	Buy → Neutral
2019-09-11	Hochstufung	Gabelli & Co	Hold → Buy
2019-07-29	Herabstufung	Stifel	Buy → Hold
2019-03-25	Hochstufung	Gabelli & Co	Sell → Hold
2018-07-31	Bestätigt	Stifel	Buy
2018-02-23	Herabstufung	Needham	Buy → Hold
2018-02-14	Herabstufung	JP Morgan	Neutral → Underweight
2017-03-01	Bestätigt	H.C. Wainwright	Buy
2017-03-01	Bestätigt	Wedbush	Outperform
2016-10-07	Eingeleitet	H.C. Wainwright	Buy
2016-08-05	Bestätigt	Wedbush	Outperform
2016-08-02	Eingeleitet	Citigroup	Buy
2016-03-02	Bestätigt	Wedbush	Outperform
2015-11-09	Bestätigt	Wedbush	Outperform
2015-09-28	Hochstufung	Gabelli & Co	Sell → Hold
2015-09-18	Herabstufung	Gabelli & Co	Hold → Sell
2015-08-10	Herabstufung	JP Morgan	Overweight → Neutral

Alle ansehen

Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten

Oct 14, 2025

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit - The Manila Times

Oct 14, 2025

Short interest data insights for Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & AI Enhanced Trading Signals - newser.com

Oct 14, 2025

Is Lexicon Pharmaceuticals Inc. stock attractive for hedge fundsWeekly Loss Report & Free Low Drawdown Momentum Trade Ideas - newser.com

Oct 14, 2025

Oct 13, 2025

Is Lexicon Pharmaceuticals Inc. building a consolidation baseMarket Sentiment Summary & Reliable Price Action Trade Plans - newser.com

Oct 13, 2025

Oct 10, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8% HigherWhat's Next? - MarketBeat

Oct 10, 2025

Lexicon Pharmaceuticals' (LXRX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat

Oct 10, 2025

Oct 08, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Down 6.3%Time to Sell? - MarketBeat

Oct 08, 2025

Lexicon (LXRX) Engages in Policy Discussion to Tackle Chronic Pa - GuruFocus

Oct 08, 2025

Lexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain Management - Quiver Quantitative

Oct 08, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - MarketScreener

Oct 08, 2025

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People With Chronic Pain - 富途牛牛

Oct 08, 2025

Oct 06, 2025

Detecting price anomalies in Lexicon Pharmaceuticals Inc. with AIEarnings Beat & Intraday High Probability Alerts - newser.com

Oct 06, 2025

Oct 05, 2025

Can you recover from losses in Lexicon Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com

Oct 05, 2025

Is Lexicon Pharmaceuticals Inc. a candidate for recovery playPortfolio Value Summary & Consistent Income Trade Recommendations - newser.com

Oct 05, 2025

Oct 04, 2025

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Oct 04, 2025

Oct 03, 2025

Is Lexicon Pharmaceuticals Inc. stock bottoming out2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com

Oct 03, 2025

What’s the recovery path for long term holders of Lexicon Pharmaceuticals Inc.Portfolio Return Summary & Long-Term Capital Growth Ideas - newser.com

Oct 03, 2025

Smart tools for monitoring Lexicon Pharmaceuticals Inc.’s price actionGap Up & High Accuracy Investment Signals - newser.com

Oct 03, 2025

Oct 02, 2025

Lexicon Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Affordable Trading Portfolio - earlytimes.in

Oct 02, 2025

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28% - simplywall.st

Oct 02, 2025

Sep 30, 2025